Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677170 · ClinicalTrials.gov registry record · Phase 1
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
A Phase 1 study of Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT00677170 is a Phase 1 study of Advanced Nonhematologic Malignancies that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 62 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT00677170, a Phase 1 study of Advanced Nonhematologic Malignancies, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.
Conditions Studied
Interventions
- DRUG MLN4924
Study Locations (3)
Texas
- Cancer Therapy & Research Center at the UT Health Science Center - San Antonio
- Institute for Drug Development - San Antonio
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677170
The ClinicalTrials.gov registry entry for NCT00677170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Nonhematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MLN4924 is the first listed.
NCT00677170 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT00677170 about?
NCT00677170 is a clinical study titled "Study of MLN4924 in Adult Patients With Nonhematologic Malignancies". This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which sta...
What is the current status of trial NCT00677170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-04. Estimated completion is 2012-12.
What conditions does trial NCT00677170 study?
This clinical trial studies the following conditions: Advanced Nonhematologic Malignancies.
What interventions are being tested in trial NCT00677170?
The interventions under investigation include: MLN4924 (DRUG).
Who is sponsoring clinical trial NCT00677170?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677170 being conducted?
This trial has 3 study locations across Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.